Anne-Geneviève Marcelin to Female
This is a "connection" page, showing publications Anne-Geneviève Marcelin has written about Female.
Connection Strength
0.111
-
Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021 02 08; 12(1):844.
Score: 0.012
-
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. J Antimicrob Chemother. 2019 05 01; 74(5):1368-1375.
Score: 0.011
-
Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases. J Clin Microbiol. 2018 06; 56(6).
Score: 0.010
-
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. J Antimicrob Chemother. 2014 Mar; 69(3):753-6.
Score: 0.007
-
Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. Clin Infect Dis. 2021 10 05; 73(7):e1762-e1765.
Score: 0.003
-
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022 01; 93(1):24-31.
Score: 0.003
-
Distinct cytokine profiles associated with COVID-19 severity and mortality. J Allergy Clin Immunol. 2021 06; 147(6):2098-2107.
Score: 0.003
-
Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. Am J Respir Crit Care Med. 2021 02 01; 203(3):307-317.
Score: 0.003
-
Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmun Rev. 2021 Feb; 20(2):102729.
Score: 0.003
-
Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19. Int J Infect Dis. 2021 Jan; 102:10-13.
Score: 0.003
-
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. J Antimicrob Chemother. 2019 09 01; 74(9):2742-2751.
Score: 0.003
-
Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study. J Antimicrob Chemother. 2019 09 01; 74(9):2716-2722.
Score: 0.003
-
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023.
Score: 0.003
-
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692.
Score: 0.003
-
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study. Pharmacotherapy. 2019 04; 39(4):514-520.
Score: 0.003
-
Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. Clin Infect Dis. 2018 11 28; 67(12):1883-1889.
Score: 0.003
-
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
Score: 0.003
-
Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. Int J Antimicrob Agents. 2019 Jan; 53(1):80-83.
Score: 0.003
-
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clin Infect Dis. 2018 05 02; 66(10):1588-1594.
Score: 0.003
-
Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia. J Antimicrob Chemother. 2018 02 01; 73(2):490-493.
Score: 0.002
-
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. J Antimicrob Chemother. 2018 Jan 01; 73(1):173-176.
Score: 0.002
-
State of the Art in HIV Drug Resistance: Surveillance and Regional Gaps. AIDS Rev. 2018 Jan-Mar; 20(1):43-57.
Score: 0.002
-
Anaplastic Kaposi's sarcoma: 5 cases of a rare and aggressive type of Kaposi's sarcoma. Ann Dermatol Venereol. 2018 Jan; 145(1):21-28.
Score: 0.002
-
High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naive HIV-infected Children in Mali. Pediatr Infect Dis J. 2017 Nov; 36(11):e258-e263.
Score: 0.002
-
Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. J Antimicrob Chemother. 2017 08 01; 72(8):2351-2354.
Score: 0.002
-
Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):448-454.
Score: 0.002
-
Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression. J Antimicrob Chemother. 2017 04 01; 72(4):1147-1151.
Score: 0.002
-
Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING. HIV Clin Trials. 2017 01; 18(1):1-16.
Score: 0.002
-
iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease. Blood. 2017 02 16; 129(7):855-865.
Score: 0.002
-
A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion. Clin Infect Dis. 2013 Sep; 57(5):745-55.
Score: 0.002
-
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients. AIDS. 2010 Nov 27; 24(18):2887-9.
Score: 0.002